Catch Bio, Inc. — SEC Form D Filing

Catch Bio, Inc. filed an SEC Form D on March 30, 2026, reporting $750K raised in Health Technology.

Form D filing details

Filing
SEC Form D
Filing date
March 30, 2026
Amount reported
$750K
Industry
Health Technology
Website
https://www.catchbio.com/

What the company does

Securities: Equity, Debt. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Many individuals are unaware of their cancer risks, which can hinder proactive health measures.

Solution

Catch provides a personalized risk assessment and actionable plans to help users understand and reduce their cancer risk.

Why now

With rising cancer rates, there is an urgent need for proactive health management and risk assessment tools.

Verdict

Investors backed Catch Bio because the rising awareness of cancer risk management offered a timely narrative, not because the competitive landscape was particularly favorable. The implicit bet was that demand for personalized health assessments would grow, but the limited upside stems from the crowded preventive healthcare space where differentiation is challenging. Investors seemed to see a potential for revenue but likely recognized that scalability may falter amid traditional players already entrenched in the market.

Source: SEC EDGAR Form D filing